Improved Survival Among Hospitalized Patients With Coronavirus Disease 2019 (COVID-19) Treated With Remdesivir and Dexamethasone. A Nationwide Population-Based Cohort Study.
Thomas Lars BenfieldJacob BodilsenChristian BrieghelZitta Barrella HarboeMarie HellebergClaire HolmSimone Bastrup IsraelsenJanne JensenTomas Østergaard JensenIsik Somuncu JohansenStine JohnsenBirgitte LindegaardJens LundgrenChristian Niels MeyerRajesh MoheyLars Møller PedersenHenrik NielsenStig Lønberg NielsenNiels ObelLars Haukali OmlandDaria PodlekarevaBirgitte Klindt PoulsenPernille RavnHaakon SandholdtJonathan StarlingMerete StorgaardChristian SøborgOle Schmeltz SøgaardTorben TranborgLothar WieseHanne Rolighed ChristensenPublished in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2021)
Treatment of moderate to severe COVID-19 during June through December that included remdesivir and dexamethasone was associated with reduced 30-day mortality and need of MV compared to treatment in February through May.